Gefitinib-d3

• 常用名: Gefitinib-d3
• 英文名: Gefitinib-d3
• CAS号: 1173976-40-3
• 分子量: 449.92100
• 密度: N/A
• 沸点: N/A
• 分子式: C₂₂H₂₁ClD₃FN₄O₃
• 熔点: N/A
• 闪点: N/A

Gefitinib-d3用途

吉非替尼-d3(ZD1839-d3)是氘标记的吉非替尼。吉非替尼(ZD1839)是一种有效、选择性和口服活性EGFR酪氨酸激酶抑制剂,IC50为33 nM。吉非替尼选择性地抑制EGF刺激的肿瘤细胞生长(IC50为54 nM),并阻断肿瘤细胞中EGF刺激的EGFR自身磷酸化。吉非替尼也诱导自噬。吉非替尼具有抗肿瘤活性[1][2]。

Gefitinib-d3名称

• 英文名: N-(3-chloro-4-fluorophenyl)-7-(methoxy-d3)-6-(3-morpholinopropoxy)quinazolin-4-amine

Gefitinib-d3生物活性

• 描述: 吉非替尼-d3(ZD1839-d3)是氘标记的吉非替尼。吉非替尼(ZD1839)是一种有效、选择性和口服活性EGFR酪氨酸激酶抑制剂,IC50为33 nM。吉非替尼选择性地抑制EGF刺激的肿瘤细胞生长(IC50为54 nM),并阻断肿瘤细胞中EGF刺激的EGFR自身磷酸化。吉非替尼也诱导自噬。吉非替尼具有抗肿瘤活性[1][2]。
• 相关类别:
  研究领域 >> 癌症
  信号通路 >> JAK/STAT信号通路 >> EGFR
  信号通路 >> 蛋白酪氨酸激酶 >> EGFR
  信号通路 >> 自噬 >> 自噬
• 体外研究: 氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
• 参考文献:

  [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54.

  [3]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23.

  [4]. Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8.

  [5]. Morgillo F, et al. Synergistic effects of 1,1-Dimethylbiguanide treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19.

  [6]. Miyake K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest. 2012;59(1-2):174-85.

  [7]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27.

  [8]. Dhar D, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.

Gefitinib-d3物理化学性质

• 分子式: C₂₂H₂₁ClD₃FN₄O₃
• 分子量: 449.92100
• 精确质量: 449.17100
• PSA: 68.74000
• LogP: 4.28650